Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DSGN | US
0.03
0.60%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.00
4.79
5.02
4.70
Design Therapeutics Inc. a preclinical-stage biopharmaceutical company engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia a monogenic autosomal recessive progressive multi-system disease that affects organ systems dependent on mitochondrial function eventually leading to neurological cardiac and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1) a dominantly-inherited monogenic progressive neuromuscular disease affecting skeletal muscle heart brain and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases such as Fragile X syndrome spinocerebellar ataxias amyotrophic lateral sclerosis frontotemporal dementia Huntington disease and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
51.5%1 month
88.1%3 months
89.3%6 months
85.1%-
-
1.16
0.01
0.01
-0.84
11.00K
-
-62.82M
283.10M
283.10M
-
-
-
-
-18.11
7.09
10.12
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.47
Range1M
2.41
Range3M
3.76
Rel. volume
0.48
Price X volume
1.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
Kamada Ltd | KMDA | Biotechnology | 5.2 | 298.89M | -0.57% | 20.04 | 3.41% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.84 | 0.76 | Cheaper |
Ent. to Revenue | 11,004.40 | 3,674.48 | Expensive |
PE Ratio | - | 38.01 | - |
Price to Book | 1.16 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 89.35 | 74.67 | Par |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 283.10M | 3.73B | Emerging |